Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterNo recent work listed

Martin Pichler

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8701-9462; OpenAlex author ID A5006483196. Sources: OpenAlex.

Their work

Papers
19 (first author 0, last author 12)
Trials
0
Grants
0
Labs led
1
Collaborators
25
Papers, trials and grants by year

2013: 5 papers · 2014: 2 papers · 2015: 2 papers · 2016: none · 2017: none · 2018: 2 papers · 2019: 2 papers · 2020: 4 papers · 2021: 1 paper · 2022: 1 paper

Papers 19

  1. Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel. Co-author DOI 10.1055/a-1548-4847↗
  2. Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis. Co-author DOI 10.1016/j.ejca.2021.03.040↗
  3. External validation of the prognostic relevance of the advanced lung cancer inflammation index (ALI) in pancreatic cancer patients. Last author DOI 10.1002/cam4.3233↗
  4. Decreased Activity of Circulating Butyrylcholinesterase in Blood Is an Independent Prognostic Marker in Pancreatic Cancer Patients. Last author DOI 10.3390/cancers12051154↗
  5. The Lipase/Amylase Ratio (LAR) in Peripheral Blood Might Represent a Novel Prognostic Marker in Patients with Surgically Resectable Pancreatic Cancer. Last author DOI 10.3390/cancers12071798↗
  6. Stage-Specific Value of Carbohydrate Antigen 19-9 and Carcinoembryonic Antigen Serum Levels on Survival and Recurrence in Pancreatic Cancer: A Single Center St… Co-author DOI 10.3390/cancers12102970↗
  7. Large platelet size is associated with poor outcome in patients with metastatic pancreatic cancer. Last author DOI 10.1515/cclm-2018-0016↗
  8. C-Reactive Protein and Neutrophil/Lymphocytes Ratio: Prognostic Indicator for Doubling overall survival Prediction in Pancreatic Cancer Patients. Co-author DOI 10.3390/jcm8111791↗
  9. Elevated amylase in plasma represents an adverse prognostic marker in patients with metastatic pancreatic cancer : A retrospective analysis. Co-author DOI 10.1007/s00508-018-1383-3↗
  10. Early Loss of Forkhead Transcription Factor, O Subgroup, Member 1 Protein in the Development of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1159/000492433↗
  11. Combination of tumour markers CEA and CA19-9 improves the prognostic prediction in patients with pancreatic cancer. Last author DOI 10.1136/jclinpath-2014-202451↗
  12. The lymphocyte to monocyte ratio in peripheral blood represents a novel prognostic marker in patients with pancreatic cancer. Last author DOI 10.1515/cclm-2014-0447↗
  13. Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients. Last author DOI 10.1038/bjc.2013.701↗
  14. Evaluation of uric acid as a prognostic blood-based marker in a large cohort of pancreatic cancer patients. Last author DOI 10.1371/journal.pone.0104730↗
  15. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Last author DOI 10.1038/bjc.2013.332↗
  16. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable as well as inoperable pancreatic cancer Last author DOI 10.1038/bjc.2013.591↗
  17. Clinico-pathological characteristics and clinical outcome of different histological types of pancreatic cancer in a large Middle European series. Last author DOI 10.1136/jclinpath-2012-201394↗
  18. External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients. Last author DOI 10.1371/journal.pone.0078225↗
  19. Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.3109/0284186x.2013.771821↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael Stotz · 15 shared papers, 2013–2022 · strength 0.99
  2. Armin Gerger · 15 shared papers, 2013–2022 · strength 0.99
  3. Peter Kornprat · 13 shared papers, 2013–2020 · strength 0.76
  4. Konstantin Schlick · 7 shared papers, 2018–2022 · strength 0.68
  5. Joanna Szkandera · 11 shared papers, 2013–2020 · strength 0.56
  6. Jakob Michael Riedl · 5 shared papers, 2020–2022 · strength 0.53
  7. Dominik Andreas Barth · 5 shared papers, 2020–2022 · strength 0.53
  8. Eva Valentina Klocker · 4 shared papers, 2019–2020 · strength 0.39
  9. Gerald Höefler · 7 shared papers, 2013–2018 · strength 0.33
  10. Richard Greil · 3 shared papers, 2019–2022 · strength 0.32
  11. Florian Moik · 2 shared papers, 2021–2022 · strength 0.23
  12. Wael Al Zoughbi · 3 shared papers, 2013–2018 · strength 0.18
  13. Eva Asamer · 2 shared papers, 2018–2020 · strength 0.17
  14. Anna Lena Lembeck · 2 shared papers, 2018–2019 · strength 0.16
  15. Jesse V. Groen · 1 shared paper, 2020 · strength 0.13
  16. Labrinus van Manen · 1 shared paper, 2020 · strength 0.13
  17. Bert A. Bonsing · 1 shared paper, 2020 · strength 0.13
  18. J. Sven D. Mieog · 1 shared paper, 2020 · strength 0.13
  19. Alexander L. Vahrmeijer · 1 shared paper, 2020 · strength 0.13
  20. Cihan Ay · 1 shared paper, 2022 · strength 0.12
  21. Lukas Weiß · 1 shared paper, 2019 · strength 0.10
  22. Alexander Egle · 1 shared paper, 2019 · strength 0.10
  23. D. Reitz · 2 shared papers, 2014–2015 · strength 0.09
  24. Christoph Tinchon · 1 shared paper, 2013 · strength 0.03
  25. Thomas Bauernhofer · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.